These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 18257906

  • 1. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.
    Kuo HC, Wang CL, Wang L, Yu HR, Yang KD.
    Pediatr Allergy Immunol; 2008 Mar; 19(2):184-5. PubMed ID: 18257906
    [No Abstract] [Full Text] [Related]

  • 2. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S, Doré PC, Sewell WA.
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract] [Full Text] [Related]

  • 3. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).
    von Gunten S, Simon HU.
    Autoimmun Rev; 2008 Jun; 7(6):453-6. PubMed ID: 18558361
    [Abstract] [Full Text] [Related]

  • 4. Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease.
    Wada Y, Kamei A, Fujii Y, Ishikawa K, Chida S.
    J Pediatr; 2006 Mar; 148(3):399-400. PubMed ID: 16615977
    [Abstract] [Full Text] [Related]

  • 5. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
    Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
    [Abstract] [Full Text] [Related]

  • 6. VI nerve palsy after intravenous immunoglobulin in Kawasaki disease.
    Rodríguez-Lozano A, Juárez-Echenique JC, Rivas-Larrauri F, Gámez-González LB, Yamazaki-Nakashimada M.
    Allergol Immunopathol (Madr); 2014 Jun; 42(1):82-3. PubMed ID: 23340202
    [No Abstract] [Full Text] [Related]

  • 7. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.
    von Gunten S, Vogel M, Schaub A, Stadler BM, Miescher S, Crocker PR, Simon HU.
    J Allergy Clin Immunol; 2007 Apr; 119(4):1005-11. PubMed ID: 17337295
    [Abstract] [Full Text] [Related]

  • 8. Role of intravenous immunoglobulin in the treatment of Kawasaki disease.
    Lo MS, Newburger JW.
    Int J Rheum Dis; 2018 Jan; 21(1):64-69. PubMed ID: 29205910
    [Abstract] [Full Text] [Related]

  • 9. [Aseptic meningitis secondary to intravenous immunoglobulin treatment in Kawasaki disease].
    García Norniella B, Morán Poladura M, Fernández Díaz M, Fernández Fernández E, Suárez Castañón C.
    An Pediatr (Barc); 2011 Jul; 75(1):79-80. PubMed ID: 21420919
    [No Abstract] [Full Text] [Related]

  • 10. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
    Shiraishi T, Yamamoto T.
    Pediatr Dermatol; 2013 Jul; 30(3):e30-1. PubMed ID: 22304420
    [Abstract] [Full Text] [Related]

  • 11. Acute renal failure and febrile rash--infectious or not? Adult Kawasaki disease (KD).
    El Karoui K, Servais A, Fadel F, Jablonski M, Fakhouri F, Lesavre P, Hummel A.
    Nephrol Dial Transplant; 2007 Mar; 22(3):949-51. PubMed ID: 17210597
    [No Abstract] [Full Text] [Related]

  • 12. Cell death modulation by intravenous immunoglobulin.
    von Gunten S, Simon HU.
    J Clin Immunol; 2010 May; 30 Suppl 1():S24-30. PubMed ID: 20405180
    [Abstract] [Full Text] [Related]

  • 13. Cardiology patient pages. Kawasaki disease.
    Baker AL, Newburger JW.
    Circulation; 2008 Aug 12; 118(7):e110-2. PubMed ID: 18695195
    [No Abstract] [Full Text] [Related]

  • 14. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, Hwang KP, Yang KD.
    Pediatr Allergy Immunol; 2009 May 12; 20(3):266-72. PubMed ID: 19438983
    [Abstract] [Full Text] [Related]

  • 15. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease.
    Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y.
    J Am Acad Dermatol; 2009 Jan 12; 60(1):146-9. PubMed ID: 19103366
    [Abstract] [Full Text] [Related]

  • 16. Marked eosinophilia in a patient with history of severe atypical Kawasaki disease.
    O'Byrne ML, Cohen MS.
    Congenit Heart Dis; 2013 Jan 12; 8(5):E130-3. PubMed ID: 22883471
    [Abstract] [Full Text] [Related]

  • 17. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Wanitkun S.
    J Pediatr; 2005 Jan 12; 146(1):149-50; author reply 150-1. PubMed ID: 15644851
    [No Abstract] [Full Text] [Related]

  • 18. Kawasaki disease: who is at risk?
    Newburger JW.
    J Pediatr; 2000 Aug 12; 137(2):149-52. PubMed ID: 10931403
    [No Abstract] [Full Text] [Related]

  • 19. Revisiting steroids in the primary treatment of acute Kawasaki disease.
    Burns JC.
    J Pediatr; 2006 Sep 12; 149(3):291-2. PubMed ID: 16939734
    [No Abstract] [Full Text] [Related]

  • 20. Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease.
    Kobayashi T, Kimura H, Okada Y, Inoue Y, Kobayashi T, Shinohara M, Morikawa A.
    Clin Exp Immunol; 2007 Apr 12; 148(1):112-8. PubMed ID: 17286760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.